SG11202003212PA - Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies - Google Patents

Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies

Info

Publication number: SG11202003212PA
Authority: SG; Singapore
Prior art keywords: antibodies; combinations
Prior art date: 2017-10-10

Application number

SG11202003212PA

Inventor

Ling Xu

Edward Seung

Lan Wu

Ronnie Wei

Gary Nabel

Zhi-Yong Yang

Tarik Dabdoubi

Béatrice Cameron

Cendrine Lemoine

Catherine Prades

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-10

Filing date

2018-10-09

Publication date

2020-05-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63963620&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202003212P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-10-09 Application filed by Sanofi Sa filed Critical Sanofi Sa

2020-05-28 Publication of SG11202003212PA publication Critical patent/SG11202003212PA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Mycology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Cell Biology (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11202003212PA 2017-10-10 2018-10-09 Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies SG11202003212PA (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201762570655P	2017-10-10	2017-10-10
US201762570660P	2017-10-11	2017-10-11
US201862676221P	2018-05-24	2018-05-24
EP18187186		2018-08-03
PCT/US2018/055084 WO2019074973A2 (en)	2017-10-10	2018-10-09	Anti-cd38 antibodies and methods of use

Publications (1)

Publication Number	Publication Date
SG11202003212PA true SG11202003212PA (en)	2020-05-28

Family

ID=63963620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202003212PA SG11202003212PA (en)	2017-10-10	2018-10-09	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies

Country Status (17)

Country	Link
US (3)	US11186649B2 (en)
EP (2)	EP3694882B1 (en)
JP (3)	JP7036909B2 (en)
KR (1)	KR20200061402A (en)
CN (2)	CN117964758A (en)
AR (1)	AR116718A1 (en)
AU (1)	AU2018348093A1 (en)
BR (1)	BR112020007002A2 (en)
CA (1)	CA3078800A1 (en)
IL (1)	IL273871A (en)
MA (1)	MA50359A (en)
MX (1)	MX2020004129A (en)
PH (1)	PH12020550408A1 (en)
SG (1)	SG11202003212PA (en)
TW (2)	TWI821202B (en)
UY (1)	UY37928A (en)
WO (1)	WO2019074973A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1914242A1 (en) *	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
TWI671315B (en) *	2011-03-28	2019-09-11	法商賽諾菲公司	Dual variable region antibody-like binding proteins having cross-over binding region orientation
KR102211837B1 (en)	2013-01-14	2021-02-03	젠코어 인코포레이티드	Novel heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
EP3928788A1 (en)	2014-11-26	2021-12-29	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cd20
HRP20211528T1 (en)	2015-10-25	2021-12-24	Sanofi	Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
TN2020000058A1 (en)	2016-04-13	2022-01-06	Sanofi Sa	Trispecific and/or trivalent binding proteins
EP3443006B1 (en)	2016-04-13	2023-08-02	Sanofi	Trispecific and/or trivalent binding proteins
SG11201912774RA (en)	2017-06-20	2020-01-30	Teneobio Inc	Anti-bcma heavy chain-only antibodies
AU2018348093A1 (en) *	2017-10-10	2020-05-28	Sanofi	Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
CA3098374A1 (en)	2018-04-25	2019-10-31	Prometheus Biosciences, Inc.	Optimized anti-tl1a antibodies
KR20210075129A (en)	2018-10-09	2021-06-22	사노피	Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infections
SG11202111012QA (en) *	2019-04-09	2021-11-29	Sanofi Sa	Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof
AU2020299600A1 (en) *	2019-07-03	2022-01-06	Crystal Bioscience Inc.	Anti-CD38 antibody and methods of use thereof
IL292419A (en)	2019-10-24	2022-06-01	Prometheus Biosciences Inc	Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021080649A1 (en)	2019-10-25	2021-04-29	Sanofi	Methods for analyzing chain mispairing in multispecific binding proteins
CN112876563B (en) *	2019-11-29	2022-08-16	康诺亚生物医药科技（成都）有限公司	Pharmaceutical composition, preparation method and application thereof
IL297644A (en)	2020-04-29	2022-12-01	Teneobio Inc	Multispecific heavy chain antibodies with modified heavy chain constant regions
UY39191A (en) *	2020-04-29	2021-11-30	Teneobio Inc	MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3192204A1 (en) *	2020-08-19	2022-02-24	Xencor, Inc.	Anti-cd28 and/or anti-b7h3 compositions
US11905332B2 (en)	2020-09-18	2024-02-20	Regeneron Pharmaceuticals, Inc.	Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof
IL305736A (en)	2021-03-09	2023-11-01	Xencor Inc	Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en)	2021-03-10	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and gpc3
TW202325743A (en) *	2021-07-14	2023-07-01	大陸商江蘇恆瑞醫藥股份有限公司	Antigen-binding molecule that specifically binds to cd38, bcma and cd3 and medical uses thereof
WO2023015170A2 (en) *	2021-08-02	2023-02-09	Tavotek Biotech (Suzhou) Ltd	Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
CA3229746A1 (en) *	2021-08-20	2023-02-23	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
WO2023246911A1 (en) *	2022-06-24	2023-12-28	北京可瑞生物科技有限公司	T cell receptor-based bispecific polypeptide molecule and use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2755395B2 (en)	1987-09-23	1998-05-20	ブリストル―マイアーズスクイブコムパニー	Antibody heteroconjugate that kills HIV-infected cells
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
PT1068241E (en)	1998-04-02	2007-11-19	Genentech Inc	Antibody variants and fragments thereof
CN1294148C (en)	2001-04-11	2007-01-10	中国科学院遗传与发育生物学研究所	Single-stranded cyctic trispecific antibody
JP5068072B2 (en) *	2003-06-27	2012-11-07	バイオジェン・アイデック・エムエイ・インコーポレイテッド	Modified binding molecule comprising a linking peptide
US9200061B2 (en) *	2004-02-06	2015-12-01	Morpho Sys AG	Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
PT2511297E (en)	2004-02-06	2015-08-24	Morphosys Ag	Anti-cd38 human antibodies and uses therefor
CN100376599C (en)	2004-04-01	2008-03-26	北京安波特基因工程技术有限公司	Recombining single chained three specific antibodies of anti CCA, anti CD 3, anti CD 28 through genetic engineering
PL2567976T3 (en) *	2005-03-23	2018-01-31	Genmab As	Antibodies against CD38 for treatment of multiple myeloma
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
MX2010013239A (en)	2008-06-03	2011-02-24	Abbott Lab	Dual variable domain immunoglobulins and uses thereof.
AU2010298025B2 (en)	2009-09-25	2016-04-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to HIV-1 and their use
RS59769B1 (en)	2010-06-09	2020-02-28	Genmab As	Antibodies against human cd38
JOP20210044A1 (en)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	Anti-cd38 antibodies
TWI671315B (en)	2011-03-28	2019-09-11	法商賽諾菲公司	Dual variable region antibody-like binding proteins having cross-over binding region orientation
WO2012154312A1 (en)	2011-05-09	2012-11-15	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Neutralizing antibodies to hiv-1 and their use
WO2012158948A1 (en)	2011-05-17	2012-11-22	The Rockefeller University	Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
CN104080805B (en)	2011-11-07	2017-02-22	美国政府健康及人类服务部	Neutralizing gp41 antibodies and their use
WO2013086533A1 (en)	2011-12-08	2013-06-13	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en)	2012-04-25	2013-10-31	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibodies to treat hiv-1 infection
US9951106B2 (en)	2012-12-04	2018-04-24	University Of Maryland, Baltimore	Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
US20140213772A1 (en)	2012-12-28	2014-07-31	Abbvie, Inc.	Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) *	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
EP2948475A2 (en)	2013-01-23	2015-12-02	AbbVie Inc.	Methods and compositions for modulating an immune response
CN105209491A (en)	2013-03-15	2015-12-30	艾伯维公司	Dual specific binding proteins directed against TNF[alpha]
CN110627907B (en) *	2013-11-04	2024-03-29	艾科诺斯科技股份有限公司	Production of heterodimeric immunoglobulins that re-target T cells
AP2016009475A0 (en)	2014-03-28	2016-09-30	Xencor Inc	Bispecific antibodies that bind to cd38 and cd3
ES2808914T3 (en)	2014-09-04	2021-03-02	Stemcell Tech Inc	Soluble antibody complexes for the activation and expansion of T lymphocytes or NK cells
CN114230668A (en)	2015-01-23	2022-03-25	赛诺菲	anti-CD 3 antibodies, anti-CD 123 antibodies, and bispecific antibodies that specifically bind to CD3 and/or CD123
US10654943B2 (en)	2015-06-02	2020-05-19	The Rockefeller University	Tri-specific antibodies for HIV therapy
HRP20211528T1 (en)	2015-10-25	2021-12-24	Sanofi	Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
CN105837688B (en) *	2015-11-20	2019-02-26	北京大学深圳研究生院	Single domain antibody and its encoding gene, immunotoxin and its encoding gene, preparation method, expression vector, application and host cell
EP3443006B1 (en) *	2016-04-13	2023-08-02	Sanofi	Trispecific and/or trivalent binding proteins
EP3575319A4 (en)	2016-12-30	2021-03-10	Shanghai Sinobio Biotech Co., Ltd.	Bifunctional molecule and use thereof
WO2018151841A1 (en)	2017-02-17	2018-08-23	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
AU2018348093A1 (en)	2017-10-10	2020-05-28	Sanofi	Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
KR20210075129A (en)	2018-10-09	2021-06-22	사노피	Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infections
US11613576B2 (en)	2019-04-09	2023-03-28	Sanofi	Trispecific binding proteins, methods, and uses thereof

2018
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en active Pending
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/en not_active Application Discontinuation
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/en unknown
- 2018-10-09 CA CA3078800A patent/CA3078800A1/en active Pending
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/en unknown
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/en active Active
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/en unknown
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/en active Pending
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/en active Active
- 2018-10-09 CN CN201880079045.9A patent/CN111788225A/en active Pending
- 2018-10-09 MA MA050359A patent/MA50359A/en unknown
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/en active Pending
- 2018-10-10 UY UY0001037928A patent/UY37928A/en not_active Application Discontinuation
- 2018-10-11 TW TW107135898A patent/TWI821202B/en active
- 2018-10-11 TW TW112124284A patent/TW202342544A/en unknown
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/en unknown
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/en active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
2023
- 2023-11-14 JP JP2023193393A patent/JP2024020377A/en active Pending

Also Published As

Publication number	Publication date
WO2019074973A2 (en)	2019-04-18
CA3078800A1 (en)	2019-04-18
US11186649B2 (en)	2021-11-30
TWI821202B (en)	2023-11-11
UY37928A (en)	2019-05-31
BR112020007002A2 (en)	2020-11-17
MA50359A (en)	2020-08-19
TW201930338A (en)	2019-08-01
AU2018348093A1 (en)	2020-05-28
US20220041746A1 (en)	2022-02-10
PH12020550408A1 (en)	2021-04-12
EP4249068A3 (en)	2023-11-22
JP7036909B2 (en)	2022-03-15
RU2020115450A (en)	2021-11-15
EP3694882A2 (en)	2020-08-19
TW202342544A (en)	2023-11-01
JP2022071087A (en)	2022-05-13
JP7387780B2 (en)	2023-11-28
WO2019074973A3 (en)	2019-06-13
KR20200061402A (en)	2020-06-02
JP2020536543A (en)	2020-12-17
JP2024020377A (en)	2024-02-14
US11365261B2 (en)	2022-06-21
IL273871A (en)	2020-05-31
CN117964758A (en)	2024-05-03
EP3694882B1 (en)	2024-06-19
MX2020004129A (en)	2020-08-20
AR116718A1 (en)	2021-06-09
CN111788225A (en)	2020-10-16
US20220275102A1 (en)	2022-09-01
EP4249068A2 (en)	2023-09-27
US20190106504A1 (en)	2019-04-11

Publication	Publication Date	Title
IL273871A (en)	2020-05-31	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
HK1258304A1 (en)	2019-11-08	Optimized anti-cd3 bispecific antibodies and uses thereof
IL278846A (en)	2021-01-31	Anti-cd3 antibodies and uses thereof
IL278844A (en)	2021-01-31	Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
IL279974A (en)	2021-03-01	Bispecific anti-bcma x anti-cd3 antibodies and uses thereof
IL267942B (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
HK1252857A1 (en)	2019-06-06	Anti-cd3 antibodies and methods of use
IL253569A0 (en)	2017-09-28	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-phf-tau antibodies and uses thereof
EP3527590A4 (en)	2020-05-27	Anti-egfr and anti-cd3 bispecific antibody and applications thereof
AU2016210068A1 (en)	2017-09-07	Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
IL283493A (en)	2021-07-29	Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and uses thereof
IL263273A (en)	2018-12-31	Anti-gitr antibodies and uses thereof
IL269134A (en)	2019-11-28	Anti-par2 antibodies and uses thereof
ZA201908072B (en)	2023-04-26	Igf-1r monoclonal antibodies and uses thereof
SG10201912366YA (en)	2020-02-27	Anti-cd3 antibody and molecules comprising the antibody
IL271128A (en)	2020-01-30	Novel anti-cd3 antibodies
EP3661555A4 (en)	2021-07-14	Bispecific antibodies and uses thereof
IL272476A (en)	2020-03-31	Anti-apelin antibodies and uses thereof
IL271398A (en)	2020-01-30	Anti-l1-cam antibodies and uses thereof
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof
IL274202A (en)	2020-06-30	Anti-glyco-muc1 antibodies and their uses